MedTrace Logo

The Use of Sugammadex in the Critically Ill

NCT03791801 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-08-21

No results posted yet for this study

Summary

Moderate and Deep neuromuscular blockade (rocuronium administered to a train of four count 0 and post-tetanic count of 1-2) in critically ill patients needing intubation or procedures can be reversed immediately and effectively by sugammadex avoiding unnecessary paralysis in an already weakened population

Conditions

  • Critical Illness

Interventions

DRUG

Sugammadex

the reversal of neuromuscular blockade with sugammadex compared to neostigmine.

DRUG

Neostigmine

the reversal of neuromuscular blockade with sugammadex compared to neostigmine.

DRUG

Rocuronium

Both groups will receive rocuronium for paralysis during intubation

DRUG

Glycopyrrolate

The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Roupen Hatzakorzian, MD MSc · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-12-01
Completion
2021-07-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03791801 on ClinicalTrials.gov